1
|
Odriozola A, San Segundo D, Cuadrado A, Hernáez T, Escrich V, Fortea JI, Martínez Á, Puente Á, Lapeña B, del Barrio M, López-Hoyos M, Crespo J, Fábrega E. SARS-CoV-2 and Liver Transplant: How Has It Behaved in This Sixth Wave? Transplantation 2022; 106:1445-1449. [PMID: 35394994 PMCID: PMC9213065 DOI: 10.1097/tp.0000000000004157] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 03/09/2022] [Indexed: 12/21/2022]
Abstract
BACKGROUND Since the declaration of a new variant of concern (VOC), Omicron, by the World Health Organization in November 2021, a quick spread has been documented worldwide, being the main VOC in the sixth wave in Spain. The Omicron variant has more transmissibility, lower virulence, and less risk of severe disease than previously described VOC. Here we analyze the current wave of severe acute respiratory syndrome coronavirus 2 infection in liver transplant recipients (LTRs). METHODS A retrospective observational study of 355 LTRs was conducted in La Rioja and Cantabria regions of Spain. Epidemiological and clinical parameters were gathered on the basis of clinical records and telephone interviews. RESULTS In the current wave of infection, a higher number of LTRs have been found to be infected than the sum of the previous 5 waves (30 versus 16 LTRs). Of the 30 infected LTRs, 29 (96.6%) had received 3 vaccine doses (mRNA based), in a median of 93 d (interquartile range, 86-108) before infection. Eight of 30 LTRs (24.0%) were asymptomatic and 21 LTRs (67.8%) were with mild symptoms with a mean duration of 4.6 d (interquartile range, 2.5-7), whereas in the unvaccinated LTRs, the symptoms were fever, nausea, vomiting, and diarrhea. Moreover, in the sixth wave, intrafamiliar transmission was the main route of infection (17/30; 56.6%), and nosocomial transmission was confirmed in 2 LTRs (6.6%). CONCLUSIONS In our series, increased transmissibility of the Omicron variant was confirmed, including nosocomial infection, with a lower risk of severe disease in LTRs. These findings could be supported by the universal vaccination of LTRs and less virulence of the Omicron variant.
Collapse
Affiliation(s)
- Aitor Odriozola
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - David San Segundo
- Department of Immunology, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Antonio Cuadrado
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Tania Hernáez
- Hepatology Unit of San Pedro Hospital, Logroño, La Rioja, Spain
| | - Víctor Escrich
- Hepatology Unit of San Pedro Hospital, Logroño, La Rioja, Spain
| | - José Ignacio Fortea
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Ángela Martínez
- Hepatology Unit of San Pedro Hospital, Logroño, La Rioja, Spain
| | - Ángela Puente
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Berta Lapeña
- Hepatology Unit of San Pedro Hospital, Logroño, La Rioja, Spain
| | - María del Barrio
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Marcos López-Hoyos
- Department of Immunology, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Javier Crespo
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Emilio Fábrega
- Department of Gastroenterology, Hepatology, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| |
Collapse
|
2
|
Odriozola A, Lamadrid-Perojo P, Cuadrado A, San Segundo D, del Barrio M, Fortea JI, Puente A, Amigo L, Fernández-Santiago R, Castillo F, Achalandabaso M, Andrés Echeverri J, Rodríguez-Sanjuan JC, López-Hoyos M, Crespo J, Fábrega E. Immune Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Liver Transplant Recipients. Transplantation 2022; 106:e341-e342. [PMID: 35323163 PMCID: PMC9213066 DOI: 10.1097/tp.0000000000004147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 02/27/2022] [Accepted: 03/03/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Aitor Odriozola
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - Patricia Lamadrid-Perojo
- Department of Immunology, Marqués de Valdecilla University Hospital, IDIVAL, Transplant and Autoimmunity Research Group, University of Cantabria, Santander, Spain
| | - Antonio Cuadrado
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - David San Segundo
- Department of Immunology, Marqués de Valdecilla University Hospital, IDIVAL, Transplant and Autoimmunity Research Group, University of Cantabria, Santander, Spain
| | - María del Barrio
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - José Ignacio Fortea
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - Angela Puente
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - Lidia Amigo
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - Roberto Fernández-Santiago
- Department of General Surgery, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria, Santander, Spain
| | - Federico Castillo
- Department of General Surgery, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria, Santander, Spain
| | - María Achalandabaso
- Department of General Surgery, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria, Santander, Spain
| | - Juan Andrés Echeverri
- Department of General Surgery, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria, Santander, Spain
| | - Juan Carlos Rodríguez-Sanjuan
- Department of General Surgery, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria, Santander, Spain
| | - Marcos López-Hoyos
- Department of Immunology, Marqués de Valdecilla University Hospital, IDIVAL, Transplant and Autoimmunity Research Group, University of Cantabria, Santander, Spain
| | - Javier Crespo
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| | - Emilio Fábrega
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, IDIVAL, Clinical and Translational Digestive Research Group, University of Cantabria, Santander, Spain
| |
Collapse
|